These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 9853453)

  • 41. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment.
    David D; Naït-Ighil L; Dupont B; Maral J; Gachot B; Thèze J
    J Infect Dis; 2001 Mar; 183(5):730-5. PubMed ID: 11181149
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of highly active antiretroviral treatment on expression of HIV-1 coreceptors and ligand levels in peripheral blood from HIV-1 infected patients in China.
    Fang J; Bai S; Wu L; Zhu X; Yao X; Jin C; Wang C
    J Int Med Res; 2013 Oct; 41(5):1560-9. PubMed ID: 24043708
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Immunologic and viral mechanisms implicated in HIV infection: the impact of treatment].
    Delfraissy JF
    Rev Prat; 1999 Oct; 49(16):1740-5. PubMed ID: 10578603
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
    Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
    Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration. Irhan Study Group.
    Amendola A; Poccia F; Martini F; Gioia C; Galati V; Pierdominici M; Marziali M; Pandolfi F; Colizzi V; Piacentini M; Girardi E; D'offizi G
    Clin Exp Immunol; 2000 May; 120(2):324-32. PubMed ID: 10792383
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort.
    Fontas E; Kousignian I; Pradier C; Poizot-Martin I; Durier C; Weiss L; Levy Y; Costagliola D; ;
    J Antimicrob Chemother; 2010 Oct; 65(10):2215-23. PubMed ID: 20702463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).
    Kilby JM; Bucy RP; Mildvan D; Fischl M; Santana-Bagur J; Lennox J; Pilcher C; Zolopa A; Lawrence J; Pollard RB; Habib RE; Sahner D; Fox L; Aga E; Bosch RJ; Mitsuyasu R;
    J Infect Dis; 2006 Dec; 194(12):1672-6. PubMed ID: 17109338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunologic control of HIV-1.
    Gandhi RT; Walker BD
    Annu Rev Med; 2002; 53():149-72. PubMed ID: 11818468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients.
    Hengge UR; Goos M; Esser S; Exner V; Dötterer H; Wiehler H; Borchard C; Müller K; Beckmann A; Eppner MT; Berger A; Fiedler M
    AIDS; 1998 Dec; 12(17):F225-34. PubMed ID: 9863864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunotherapy and therapeutic vaccines in HIV infection.
    García F; Ruiz L; López-Bernaldo de Quirós JC; Moreno S; Domingo P
    Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():84-104. PubMed ID: 16373008
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adoptive therapy with purified CD8 cells in HIV infection.
    Herberman RB
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):35-40. PubMed ID: 1535457
    [No Abstract]   [Full Text] [Related]  

  • 52. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
    Lévy Y; Gahéry-Ségard H; Durier C; Lascaux AS; Goujard C; Meiffrédy V; Rouzioux C; El Habib R; Beumont-Mauviel M; Guillet JG; Delfraissy JF; Aboulker JP;
    AIDS; 2005 Feb; 19(3):279-86. PubMed ID: 15718838
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment.
    Calarota SA; Leandersson AC; Bratt G; Hinkula J; Klinman DM; Weinhold KJ; Sandström E; Wahren B
    J Immunol; 1999 Aug; 163(4):2330-8. PubMed ID: 10438897
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.
    Kostense S; Otto SA; Knol GJ; Manting EH; Nanlohy NM; Jansen C; Lange JM; van Oers MH; Miedema F; van Baarle D
    Eur J Immunol; 2002 Apr; 32(4):1080-9. PubMed ID: 11920575
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thymic volume is associated independently with the magnitude of short- and long-term repopulation of CD4+ T cells in HIV-infected adults after highly active antiretroviral therapy (HAART).
    Ruiz-Mateos E; Rubio A; Vallejo A; De la Rosa R; Sanchez-Quijano A; Lissen E; Leal M
    Clin Exp Immunol; 2004 Jun; 136(3):501-6. PubMed ID: 15147352
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant Interleukin-2 (rIL-2), aldesleukin.
    Baigent G
    J Biotechnol; 2002 May; 95(3):277-80. PubMed ID: 12007868
    [No Abstract]   [Full Text] [Related]  

  • 57. The role of immunotherapy in the treatment of HIV.
    Saag MS
    AIDS; 2001 Feb; 15 Suppl 2():S1-3. PubMed ID: 11424970
    [No Abstract]   [Full Text] [Related]  

  • 58. Drug watch.
    Whitson S
    Posit Aware; 1999; 10(1):18-9. PubMed ID: 11366516
    [TBL] [Abstract][Full Text] [Related]  

  • 59. On the global dynamics of a model for tumor immunotherapy.
    Kirschner D; Tsygvintsev A
    Math Biosci Eng; 2009 Jul; 6(3):573-83. PubMed ID: 19566127
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-lasting HIV suppression by combined immunotherapy.
    Jaworski JP
    Lancet HIV; 2018 Dec; 5(12):e680. PubMed ID: 30527324
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.